|

Multiple Sclerosis Clinical Trials in Massachusetts

41 recruiting studies across 1 city

Browse by City

Boston
41 trials

All Trials in Massachusetts

Phase
Trial Phase Dist.
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.Phase 3<1 mi
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabPhase 3<1 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)—<1 mi
Ocrelizumab Discontinuation in Relapsing Multiple SclerosisPhase 4<1 mi
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis PatientsPhase 2<1 mi
Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability StudyN/A<1 mi
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 YearsPhase 2<1 mi
AMX0114 in Adult Participants With Amyotrophic Lateral SclerosisPhase 1<1 mi
Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis SubjectsPhase 1<1 mi
Vascular Mechanisms, Functional Outcomes, & Exercise Among Persons With Multiple Sclerosis With HypertensionN/A<1 mi
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)Phase 2<1 mi
Glucose Consumption in MS Using [F-18]FDG-PETPhase 4<1 mi
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk—<1 mi
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisPhase 3<1 mi
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple SclerosisPhase 4<1 mi
Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis—<1 mi
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPhase 1<1 mi
Efgartigimod for the Treatment of Acute Optic NeuritisPhase 2<1 mi
Assessment of Synaptic Density in MSEarly 1<1 mi
TSC Biosample Repository and Natural History Database—<1 mi
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple SclerosisPhase 2<1 mi
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention StudyPhase 2<1 mi
Molecular Imaging of NET Using [C-11]MRB-PET in MSPhase 1/2<1 mi
Care in Multiple Sclerosis (MS)—<1 mi
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic SclerosisPhase 2<1 mi
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric DiseasesPhase 1/2<1 mi
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe EpilepsyPhase 1/2<1 mi
Genes and Environment in Multiple Sclerosis—<1 mi
Study of COYA 302 for the Treatment of ALSPhase 2<1 mi
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)Phase 1<1 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPhase 2<1 mi
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease—9 mi
Confirmatory Trial for Alleviating Fatigue in Multiple SclerosisN/A9 mi
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis—9 mi
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives—9 mi
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisPhase 323 mi
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis SpasticityPhase 223 mi
A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)—23 mi
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)Phase 339 mi
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple SclerosisPhase 139 mi
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)Phase 239 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.